EMA — authorised 17 July 2017
- Marketing authorisation holder: LEO Pharma A/S
- Status: approved
🇪🇺 Kyntheum in European Union
EMA authorised Kyntheum on 17 July 2017
Marketing authorisations
EMA — authorised 17 July 2017
- Application: EMEA/H/C/003959
- Marketing authorisation holder: LEO Pharma A/S
- Local brand name: Kyntheum
- Indication: Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
- Status: approved
Kyntheum in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Kyntheum approved in European Union?
Yes. EMA authorised it on 17 July 2017; EMA authorised it on 17 July 2017.
Who is the marketing authorisation holder for Kyntheum in European Union?
LEO Pharma A/S holds the EU marketing authorisation.